Navigation Links
LA BioMed researcher says 'unexpected' increase in cancer risk found
Date:3/4/2008

TORRANCE An increased cancer risk in post-menopausal women after they stopped taking combined hormone therapy was an unexpected finding in a study that will be reported in the March 5 edition of the Journal of the American Medical Association (JAMA), said Rowan T. Chlebowski, M.D., Ph.D., a Los Angeles Biomedical Research Institute (LA BioMed) lead investigator who contributed to the study.

This latest study reinforces the original finding that combined hormone therapy of estrogen plus progestin should not be taken for the purpose of reducing disease in post-menopausal women, Chlebowski said. These findings also reinforce the need for monitoring for cancer in women who have taken the combination of estrogen plus progestin.

Dr. Chlebowski is a medical oncologist who has led several prior reports focusing on hormone effects on malignancies, including breast and colorectal cancer. He was a member of the team of researchers, led by Gerardo Heiss, M.D., of the University of North Carolina, Chapel Hill, N.C., who authored the March 5 JAMA report on a follow-up study of post-menopausal women enrolled in the Womens Health Initiative. Dr. Chlebowski is available for comment for reporters seeking further insight into the studys findings.

About the Womens Health Initiative

The Womens Health Initiative (WHI) trial began in 1993 to measure the effect of estrogen plus progestin on reducing disease in post-menopausal women. It included 16,608 postmenopausal women and assessed whether conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) prevents heart disease and hip fractures and increases the risk of breast cancer.

The trial was stopped in 2002 when data indicated an increased risk of breast cancer and a failure to demonstrate an overall health benefit of the therapy. Further analysis showed that women taking the two hormones had higher risks of cardiovascular disease, coronary heart disease, stroke and venous thromboembolism and lower risks of fracture and colorectal cancer.

About the Follow-Up Study

After stopping intervention, WHI followed the trial participants using the same study protocol of semi-annual monitoring to identify and classify study outcomes, in order to evaluate the effects of stopping hormone therapy.

Post intervention information for the period July 8, 2002 to March 31, 2005 was available on 95% of the women. The JAMA article reports on health outcomes at three years after the intervention was stopped (mean of 2.4 years of follow-up).

In the three years after stopping hormone therapy women who previously used estrogen plus progestin no longer had an increased risk of cardiovascular disease (heart disease, stroke, and blood clots) compared with women on placebo.

The lower risk of colorectal cancer and fractures seen during the trial in women who previously used estrogen plus progestin disappeared after stopping the combined hormone therapy.

But the risk of all cancers combined in women who previously used estrogen plus progestin increased after stopping the intervention compared to those previously on placebo. This was due to increases in a variety of cancers, including lung cancer.

After stopping the hormone therapy, mortality from all causes was somewhat higher in women who previously used estrogen plus progestin compared with those taking a placebo.


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
3. Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science
4. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
5. Lung Cancer Alliance Urges Inclusion of $5 Billion for Biomedical Research in Economic Stimulus Package
6. BioMed Central bolsters radiology image collection
7. New nanotube findings by Stanford researchers give boost to potential biomedical applications
8. American Red Cross Announces New Leader for Biomedical Services
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
11. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... eliminate cyber threats in real-time, today announced a strategic partnership with Paramount ... to monitor, respond and protect their critical information assets and infrastructure, in a ...
(Date:1/24/2017)... ... ... Bellus Medical, a leader in medical aesthetics, today announced that Marek Dobke, M.D., ... will provide physician oversight for in-house clinical studies and hands-on device training, among other ... Professor of Surgery at UC San Diego Health and is a board certified plastic ...
(Date:1/24/2017)... ... 24, 2017 , ... The University of Iowa, long recognized as one of ... program that provides teachers with the specific skills and training they need to teach ... for post-baccalaureate students and HigherEducation.com is working to ensure that this new program is ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com recently gave a ... premenstrual syndrome, or PMS . , Most women of child-bearing age will experience ... constipation, irritability, headaches, fatigue, and other discomfort. For some women, the effects ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Allied Market Research, titled, "Cold Chain Logistics Market by ... & Frozen Dessert, Meat, Fish & Sea Food, Drugs ... Industry Forecasts, 2014-2022," projects that the global cold chain ... 2022, growing at a CAGR of 16% (2016 to ...
(Date:1/24/2017)... January 24, 2017 Analysis of the Liquid ... Liquid Biopsies - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover How ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017 /PRNewswire/ ... leader in the engineering and industrialization of biology to improve ... announced that it has entered into a definitive agreement to ... a clinical-stage company and pioneer in the development of AdenoVerse™ ... and expand upon GenVec,s expertise in adenoviral vectors and cGMP ...
Breaking Medicine Technology: